Accumulation of insoluble alpha-synuclein aggregates in the brain is characteristic of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Although numerous studies on the aggregation properties of alpha-synuclein have been reported, little is known about its degradation so far. In view of proteolytic degradation, we have found that the serine protease neurosin (kallikrein-6) degrades alpha-synuclein and co-localizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions. In vitro study showed that neurosin prevented alpha-synuclein polymerization by reducing the amount of monomer and also by generating fragmented alpha-synucl eins that themselves inhibited the polymerization. Upon cellular stress, neurosin was released from mitochondria to the cytosol, which resulted in the increase of degraded alpha-synuclein species. Down regulation of neurosin caused accumulation of alpha-synuclein within cultured cells. Thus we concluded that neurosin plays a significant role in physiological alpha-synuclein degradation and also in the pathogenesis of synucleinopathies. 
Introduction
Protein aggregation and filament formation are the hallmarks of many neurodegenerative diseases. The formation of these disease-specific amyloid structures is thought to play an important role in the pathogenesis of these diseases (1-3). Whether or not cell death is a direct effect of the accumulation of the aggregated proteins is still controversial; however, most studies suggest that aggregated proteins can affect cell viability through several pathways (4, 5) . For example, recent studies have shown that aggregation of polyglutamine containing proteins or alpha-synuclein cause proteasome dysfunction, and this might lead to neurodegeneration (6) (7) (8) .
Accumulation of insoluble alpha-synuclein in the brain is observed in Parkinson's disease (PD), Dementia with Lewy bodies and multiple system atrophy (MSA) (9-13). These synucleinopathies show distinct clinical symptoms from each others; however, they appear to share common cell death mechanism related to alpha-synuclein aggregation. Alpha-synuclein is a small acidic synaptic protein composed of 140 amino acid residues, including 7 incomplete repeats of 11 amino acids and a core sequence of KTKEGV at the amino terminus (14) . In vitro generated alpha-synuclein, particularly the mutant A53T protein, forms aggregates under certain conditions (15) (16) (17) . In vivo studies have shown that mice and flies generated to over-express alpha-synuclein within their neurons develop neurological disorders that mimics Parkinson's Although much has been learned about in vitro protein aggregate formation, the mechanism of in vivo alpha-synuclein aggregate formation is still unclear, because simple over-expression of alpha-synuclein rarely forms aggregate in cultured cells. It can be speculated that unlike other proteins prone to aggregate, such as long polyglutamine stretch containing proteins, efficient degradation of alpha-synuclein prevents its aggregation under normal conditions. Alternatively, post-translational modification of alpha-synuclein might be needed for its aggregation. For instance, i t has been reported that insoluble alpha-synuclein is nitrated or phosphorylated, and these modifications accelerate the accumulation of aggregates in vitro (22, 23) .
The level of alpha-synuclein messenger RNA is not altered in synucleinopathies (24, 25), suggesting that rather than increased protein expression, protein modification or impairment of its degradation might be related to the pathogenesis of the disease. So far, very little has been known about the degradation of alpha-synuclein. Some studies have suggested that there might be a degradation pathway for alpha-synuclein other than the ubiquitin proteasome pathway (26, 27 ). To shed light on this issue, we searched for the protease that degrades alpha-synuclein and found that alpha-synuclein is degraded by the serine protease neurosin in vitro and in vivo, and neurosin also accumulated in alpha-synuclein inclusions in diseased brain. 
Results
Fragmented alpha-synucleins are found in mice brains.
While analyzing the expression of alpha-synuclein in normal mice brain, we found that there were very small, but significant amount of anti-alpha-synuclein antibody reactive low molecular weight bands in immunoblots (Fig. 1a) . We confirmed the presence of these bands using panel of antibodies and also made sure that these bands are not artifacts using various sets of protease inhibitors.
Neurosin degrades alpha-synuclein.
We hypothesized that the low molecular weight bands were degraded alpha-synuclein and started exploring the biological significance of these species. According to a previous report, a serine protease neurosin (kallikrein-6) immunoreactivity was present in Lewy bodies (28). To determine whether kallikreins can specifically degrade alpha-synuclein, recombinant alpha-synuclein was incubated with HEK-293 cell lysates together with various protease inhibitors. Serine protease inhibitors such as aprotinin, phenylmethane sulfonyl fluoride (PMSF), leupeptin, 4 -(2-aminoethyl)-benzenesulfonyl flu oride (AEBSF) had inhibitory effect on alpha-synuclein degradation activity, while ethylenediaminetetraacetic acid (EDTA), pepstatinA and ethylene glycol-bis (beta-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA) had no effect (Fig. 1b) , suggesting that the protease was a serine protease. Furthermore, when kallikrein inhibitor was added to the reaction, it inhibited the degradation activity dose-dependently, and also purified kallikrein itself could degrade alpha-synuclein (Fig. 1c) . From these results, we hypothesized that neurosin (kallikrein-6) is an alpha-synuclein degrading enzyme.
Neurosin is present in Lewy bodies and glial cytoplasmic inclusions.
For further experiments, antibodies were generated against human neurosin (Fig. 1d) .
To see if neurosin was involved in synucleinopathies, we stained postmortem brain sections with the antibodies. Anti-neurosin antibody clearly stained both Lewy bodies in Parkinson's disease (PD), neurodegeneration with brain iron accumulation type 1 (Type1 NBIA) and glial cytoplasmic inclusions in multiple system atrophy (MSA) (Fig. 1e-g ). Interestingly, anti-neurosin antibody stained the Lewy bodies preferably at the core of the inclusion, while staining by alpha-synuclein antibody was mainly at the peripheral part of the structure. In contrast, both antibodies stained glial cytoplasmic inclusions homogeneously. Thus, we supposed that neurosin is involved in the development of synucleinopathies through alpha-synuclein degradation process.
Alpha-synuclein fragments produced by neurosin inhibit alpha-synuclein polymerization.
To investigate the role of neurosin in alpha-synuclein degradation, we performed in vitro alpha-synuclein polymerization experiment using recombinant proteins. When incubated at 37ºC at a concentration of 10µg/mL, purified alpha-synuclein monomer started to form SDS- resistant polymers from the time point of 8 hours (Fig. 2a) . Forty eight hours was enough to generate 95% of the dimers produced by 96 hours, so that for further experiments, time point of 48hours was selected to evaluate the polymerization.
To investigate the effect of neurosin in the polymerization process, recombinant neurosin was added to the alpha-synuclein monomer solution, and the mixture was incubated at 37ºC for 48 hours. Neurosin dose-dependently inhibited the polymerization of alpha-synuclein (Fig. 2b) . To determine whether the inhibition effect is due to the presence of proteolytic fragments, or due to a reduction in the level of monomer, we mixed full length alpha-synuclein with various concentrations of fragmented alpha-synuclein and incubated at 37ºC for 48 hours. For these experiments, we generated fragmented alpha-synuclein without protease activity by heat treatment of neurosin digested alpha-synuclein. Heat treatment could completely abolish the residual proteolytic activity (Fig 2c) . Addition of those fragmented alpha-synucleins inhibited the polymerization, both when fragmented alpha-synucleins were added to achieve a total alpha-synuclein amount of 200ng (both monomer and fragments) (Fig 2d) and when they were added to 200ng of monomeric alpha-synuclein (Fig 2e) . Thus we concluded that neurosin has an inhibitory effect on alpha-synuclein polymerization from reducing the monomer substrate by proteolytic degradation as well as producing fragmented alpha-synucleins which themselves have inhibitory effect on polymerization. Electron microscopic studies were done to evaluate the effect further. Polymerized alpha-synuclein formed "sphere" like structures (Fig. 2f, left panel) , but those structures were rarely seen when neurosin was added to the polymerization mixture (Fig. 2f, right panel) .
The ability of neurosin to cleave various synucleins was tested. Low concentrations of neurosin digested A53T mutant synuclein less efficiently than the wild type alpha-synuclein (Fig. 2g ).
This result led us to the conclusion that neurosin has less proteolytic activity on pathological mutant of alpha-synuclein, suggesting that the impairment of neurosin degradation pathway might be involved in the disease process.
Neurosin is released from mitochondria to cytosol during cellular stress and regulates alpha-synuclein degradation.
To study sub-cellular localization of neurosin, immunohistochemical study on HEK-293 cells was performed and revealed that part of the cytoplasmic anti-neurosin staining of co-localized with cytochrome C staining (Fig. 3a) . In sub-cellular fractionation experiments, neurosin was found in the mitochondrial and microsomal fractions but not in the nuclear or cytosolic fractions (Fig 3b) , suggesting that nuclear staining in Fig.3a may be non-specific. with ultra violet (UV) light most effectively released neurosin from the mitochondria to the cytosol (Fig.3c) . The release was confirmed by immunohistochemistry (Fig.3d) .
To examine this phenomenon more closely, cells were exposed to UV light and collected 0, 4 and 8 hours later. Increase in the levels of fragmented alpha-synuclein was shown to accompany the release of neurosin into the cytosolic fraction (Fig.3e) .
To see whether neurosin is regulating alpha-synuclein degradation, RNA interference was performed in order to reduce cellular neurosin levels. Down-regulation of neurosin in SH-SY5Y cells by siRNA led to i ncrease the expression levels of intact alpha-synuclein, while control siRNA had no effect on neurosin or alpha-synuclein levels (Fig. 3f) . The experiment confirmed the role of neurosin in alpha-synuclein degradation.
Neurosin and alpha-synuclein co-localize in vivo.
To investigate whether neurosin could interact with alpha-synuclein under physiological condition, we immunoprecipitated these proteins from mouse brain lysate.
Anti-alpha-synuclein antibody successfully immunoprecipitated neurosin and conversely, anti-neurosin antibody immunoprecipitated alpha-synuclein (Fig. 4a) .Furthermore, alpha-synuclein rich fractions were prepared from mouse brain using a sucrose gradient method (32, 33) and tested for the co-existence of neurosin in these fractions. Neurosin was demonstrated to exist in these fractions (Fig. 4b) . To confirm the co-localization in situ, mice at Pennsylvania State University on February 23, 2013 http://hmg.oxfordjournals.org/ Downloaded from brain striatum was stained with the antibodies to alpha-synuclein and neurosin to show that these two proteins co-localized (Fig. 4c) . The result suggests that both alpha-synuclein and neurosin co-localize at axon terminus. Thus we concluded that these proteins could interact in the normal brain. 
Discussion

Neurosin degrades alpha-synuclein
Alpha-synuclein is a very abundant protein in the central nervous system; however, its physiological role is still ambiguous. Several studies have suggested that when alpha-synuclein is present in the cytoplasm, it acts as a regulator of signal transduction (34-36) , and when bound to membrane at the synaptic terminus, it regulates synaptic vesicle release (37, 38) . These studies have provided significant information about the protein, however, very little has been known about its production and degradation (26, 27).
The presence of low molecular weight bands reactive with anti-alpha-synuclein in mice brain lysates gave us a hint for alpha-synuclein degradation process. As we investigated the significance of fragmented alpha-synuclein, we performed a literature search and found that an immunohistochemical study had reported protease neurosin (kallikrein-6) immunoreactivity in Lewy bodies (28). Neurosin is a serine protease preferentially expressed in brain, especially in neurons and oligodendrocytes (29, 30, 39-41). Serine proteases are known to recognize a lysine residue. Interestingly, alpha-synuclein is a lysine rich protein, characterized by repeats of the sequence KTKEGV. Inhibition study of alpha-synuclein degrading activity from HEK-293 cells by panels of protease inhibitors clearly showed that the activity is inhibited by serine protease inhibitors. Kallikrein inhibitor also showed dose-dependent inhibition of this degradation, suggesting that these fragments were generated from synuclein by protease of kallikrein family, especially neurosin. Moreover, we tried to prepare this degrading activity enriched fraction from the cell lysates and found neurosin in the final concentrated fraction (data not shown).
These findings encouraged us to generate anti-neurosin antibodies, and we found that these antibodies stained alpha-synuclein inclusions in Lewy bodies in PD and neurodegeneration with brain iron accumulation type1, as well as glial cytoplasmic inclusions in MSA, suggesting that the protease might have a significant role in the synucleinopathies. Interestingly, in Lewy bodies, neurosin immunoreactivity seemed to be located at the core of the inclusion, suggesting that neurosin might be involved early in the disease process.
Neurosin has a signal peptide which is thought to be cleaved upon secretion from cells; however, immunohistochemical studies have revealed that a significant amount of neurosin exists in cell bodies (29). Our result also showed that neurosin was present in mitochondria and microsomes in sub-cellular fractionation and immunohistochemically in mitochondria. Neurosin enriched fraction from the mitochondrial and microsomal fraction also contained alpha-synuclein degrading activity (data not shown), suggesting that neurosin is a major degrading enzyme for alpha-synuclein.
If neurosin is abundant inside mitochondria, while cytosolic fraction is very low, there seems that the chance for the protease to degrade alpha-synuclein might be low. However, RNA interference Immunoprecipitation study of brain lysate by anti-synuclein which precipitated neurosin further suggests that alpha-synuclein and neurosin interact directly or both molecules associate with same membrane and synuclein could interact with neurosin as a substrate in vivo.
In the disease brains of synucleinopathy, neurosin co-localized with alpha-synuclein aggregates.
This result also suggests that very small amount of neurosin could interact with alpha-synuclein in the cytoplasm constitutively and also after released from mitochondria under stress condition.
Fragmented alpha-synuclein inhibits polymerization of alpha-synuclein
As reported previously, recombinant alpha-synuclein forms polymers upon in vitro incubation (15) . Our recombinant protein also formed dimers after 8 hours of incubation, and the level of oligomers increased with time. During this polymerization reaction we added neurosin and found a dose-dependent inhibition of the formation of alpha-synuclein polymers. The addition of neurosin was not essential for inhibition of dimer formation; the fragmented alpha-synuclein itself had the effect of inhibiting polymerization. Electron microscopy showed that "spheres" (42) were not formed by neurosin treated alpha-synuclein, indicating that fragmented alpha-synuclein inhibited fibril formation in its early phase.
The inhibitory role of neurosin for alpha-synuclein aggregation formation might appear to be contradictory to the colocalization with synuclein aggregates. There are two possible explanations for this. One is that the in vitro experiment showed inhibition only when excessive fragments were added to the mixture and the amount of fragmented alpha-synuclein in vivo is not enough to prevent the entire fibrillization process. Another possibility is that the entire polymerization process prevails over the inhibitory processes of various cellular efforts to prevent alpha-synuclein aggregation and neurosin only associated with the preformed aggregates as substrates.
A protective role of neurosin against aggregate formation is interesting because another mitochondrial protein, cytochrome c, was reported to be stimulator of alpha-synuclein aggregation and localizes in Lewy bodies in Parkinson's disease (43). It is possible that in Lewy body bearing disorders, chronic apoptotic stressors release both protective (neurosin) and accelerating (cytochrome c) factors from mitochondria and both accumulate in Lewy bodies. In this regard, neurosin, located on chromosome 19 (39), may be a candidate gene for risk factors of synucleinopathy.
In summary, we have identified neurosin as an alpha-synuclein degrading enzyme. It 
Antibodies
Anti-alpha-synuclein antibodies were raised against peptide sequences of human alpha-synuclein MPVDPDNEAYEMPSE (MC-36) and EGYQDYEPEA (MC-37). Rabbit antibodies against neurosin were also generated by immunizing rabbits with synthetic peptide of human neurosin sequences and affinity purified with the peptides. The sequences of the peptides used were LVHGGPCDKTSHPYQAA (NS-5105) and LGKHNLRQRESSQEQSS (NS-5106). To determine the specificity of the antibodies, SH-SY5Y cells were transfected with pcDNA4 vector (Invitrogen, Carlsbad, CA) inserted with neurosin cDNA and the lysate was subjected to immunoblotting. S1 antibodies were generated as previously described (35). Rabbit antibody against the NAC portion of alpha-synuclein EQV-1 was a kind gift from Dr. Ueda For V5 tagged synuclein, alpha-synuclein was subcloned to pBAD TOPO (Invitrogen).
Recombinant protein was expressed in LMG194 (Invitrogen) with 0.02% arabinose induction and purified by nickel chelating column.
Cell culture and sub-cellular fractionation
HEK-293 and SH -SY5Y cells were grown in Dulbecco's modified Eagle medium (Sigma, St.
Louis, MO) supplemented by 10% fetal bovine serum or calf serum (BIO Whittaker, Walkersville, MD, USA) at 37ºC in 95% air, 5% CO 2 . For sub-cellular fractionation, cells were homogenized by teflon homogenizer with 10 strokes in 10mM Tris-HCl pH6.8, 150mM MgCl 2 , 10mM KCl, 250mM sucrose and spun at 1,000g for 5 minutes. The pellet was retained as the nuclear fraction; the supernatant was spun at 5,000g for 10 minutes to produce the crude mitochondrial pellet. The resulting supernatant was spun at 100,000g for 1 hour to separate the cytosolic fraction (supernatant) from the fraction containing microsomes (pellet). The crude mitochondrial fraction was then washed with 10mM Tris-HCl pH 6.7, 250mM sucrose, 150mM
MgCl 2 and ultrasonically lysed in 50mM sodium phosphate buffer and kept as mitochondrial fraction. 
Alpha-synuclein in vitro degradation experiment
Ten µg/mL of recombinant synuclein (alpha wild type, A30P, A53T and beta) was mixed with 0.5mg/mL HEK-293 lysate or indicated amount of kallikrein (Sigma) in 50mM sodium phosphate buffer (pH 7.4) at 37°C for 2hours. When indicated, protease inhibitors such as 5µg/mL aprotinin, 5mM EDTA, 2mM PMSF, 5µg/mL leupeptin, 5µg/mL pepstatinA, 5mM EGTA, Complete (Roche) or 5mM AEBSF were added. The mixtures were then mixed with SDS-PAGE sample buffer, incubated at 95°C for 5minutes. Ten µL of the reaction mixture was applied to SDS-PAGE and immunoblotting was done with S1 antibodies.
Alpha-synuclein polymerization and polymerization inhibition experiment
For alpha-synuclein polymerization, 10µg/mL of recombinant alpha-synuclein was incubated at 37ºC in 50mM sodium phosphate buffer, pH 7.4 and incubated at 37 °C for indicated time.
Ten µg/mL or indicated amount of monomer alpha-synuclein was mixed with fragmented alpha-synuclein at concentration of 10µg/mL or more for 48hours at 37ºC. The mixtures were then mixed with SDS-PAGE sample buffer, incubated at 95°C for 5minutes. Ten µL of the reaction mixture was applied to SDS-PAGE and immunoblotting was done with S1 antibodies.
Neurosin heat inactivation experiment
To generate neurosin inactivated fragmented alpha-synuclein , 10µg/mL r ecombinant alpha-synuclein was incubated with 1µg/mL recombinant neurosin for 2 hours and heated at 95°C for 5 minutes. Then 5µg/mL of recombinant V5 tagged alpha-synuclein was added to the solution and incubated for 8 hours at 37ºC. The residual proteolytic activity was monitored with the degradation of V5 tagged alpha-synuclein by anti-V5 antibody blot.
Cell stress experiment
SH-SY5Y cells were incubated with 600µM hydrogen peroxide, 25mM S-nitroso-N-acetylpenicillamine, 3mM 2-mercaptoethanol, 10mg/mL tunicamycin, 100µg/mL methyl methanesulfonate, 300mM sorbitol or irradiated with UV light at 40J/m 2 or 1000J/m 2 using a Stratalinker UV cross-linker (Stratagene, La Jolla, CA). After exposure of SH-SY5Y cells to various stresses, cytosolic fractions were obtained from the cells as described.
RNA interference
Small interference RNA targeted against 88-108bp of the human neurosin open reading frame (5'-aagacatctcacccctaccaa -3') was generated using siRNA construction kit (Ambion, Austin, TX). BLAST search analysis was done to confirm that the sequence was highly specific to neurosin. Two other different sequences from neurosin was tested for RNAi efficiency, but failed to show any reductions in the level of neurosin. For control siRNA, this sequence was randomized (5'-aaccactaaccgcaccatatc -3'). Two hundred pmol of siRNA was transfected using
Oligofectamine reagent (Invitrogen) as described by the manufacturer. 
Immunoprecipitation
Mice brains lysates were obtained as described previously. 1µg of antibody or normal rabbit serum was added to 100µg of lysate and incubated for 4 hours at 4ºC. Then 20µL of protein G agarose (Invitrogen) was added and incubated for 2hours. Then the lysates were spun at 20,000g
and the pelleted protein G agarose was washed by brain lysis buffer for 4 times and subjected to SDS-PAGE and blotted with NS-5106 and MC-36 antibodies.
Preparation of alpha-synuclein rich fraction from mice brain
Mice brains were homogenized in 10 times volume / weight of buffered sucrose (320mM sucrose, 4mM HEPES-NaOH, pH 7.3) with Complete (Roche) by teflon homogenizer with 10 strokes and centrifuged for 10minutes at 800g. The supernatant was then centrifuged at 9,200g for 15minutes.
The supernatant was centrifuged at 10,200g for 15minutes to obtain the pellet, which was then resuspend in buffered sucrose and lysed by adding 9 volumes of H 2 O, homogenized and adjusted to 10mM HEPES-NaOH, pH 7.2 and kept on ice for 30minutes. This was then centrifuged for 20minutes at 25,000g. The supernatant was centrifuged at 165,000g for 2 hours and then the pellet was resuspended in 40mM sucrose and subjected to 100mM to 800mM sucrose gradient in 4mL scale and spun at 65,000g for 5 hours. Out of 500 µL each fractions, 20µL of 200mM to 400mM bands were subjected as alpha-synuclein rich fraction to SDS-PAGE and blotted with NS-5106 and MC-37 antibodies. 9. Arima, K., Ueda, K., Sunohara, N., Arakawa, K., Hirai, S., Nakamura, M., Recombinant alpha-synuclein was incubated with HEK-293 cell lysate at 37ºC for 2hours.
Various protease inhibitors were added to the reaction mixture. Five µg/mL aprotinin, 2mM
PMSF, 5µg/mL leupeptin, 5mM AEBSF and Complete (Roche) inhibited the degradation, while 5mM EDTA, 5µg/mL pepstatinA and 5mM EGTA had no effect.
c) Kallikrein degrades alpha-synuclein.
Kallikrein inhibitor inhibited the protease activity of HEK-293 cell lysate in a dose dependent 
